Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 403

Similar articles for PubMed (Select 15015893)

1.

The role of immunomodulatory drugs in multiple myeloma.

Anderson KC.

Semin Hematol. 2003 Oct;40(4 Suppl 4):23-32. Review.

PMID:
15015893
2.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.

Blood. 2002 Nov 1;100(9):3063-7.

3.

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

Barlogie B.

Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

PMID:
15015894
4.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
5.
6.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K.

Semin Hematol. 2003 Oct;40(4 Suppl 4):3-7. Review.

PMID:
15015890
7.

Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.

Dimopoulos MA, Anagnostopoulos A.

Semin Hematol. 2003 Oct;40(4 Suppl 4):8-16. Review.

PMID:
15015891
8.

The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.

García-Sanz R, González-Fraile MI, Sierra M, López C, González M, San Miguel JF.

Hematol J. 2002;3(1):43-8.

PMID:
11960395
9.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

10.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N.

Ann Oncol. 2001 Jul;12(7):991-5.

11.

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.

Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M.

Haematologica. 2002 Apr;87(4):408-14.

12.

[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].

Wu KL, Schaafsma MR, Lokhorst HM, Wijermans PW, van der Holt B, Sonneveld P.

Ned Tijdschr Geneeskd. 2002 Aug 3;146(31):1445-8. Dutch.

PMID:
12190011
13.

Lenalidomide in the treatment of multiple myeloma: a review.

Armoiry X, Aulagner G, Facon T.

J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x. Review.

PMID:
18452408
14.

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.

Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J.

Br J Haematol. 2003 Aug;122(4):607-16.

PMID:
12899716
15.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

16.

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.

Raje N, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1239-47. Review.

PMID:
17020458
17.

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.

Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M.

Eur J Haematol. 2005 Nov;75(5):391-5.

PMID:
16191088
18.

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M.

Haematologica. 2001 Apr;86(4):399-403.

19.

Lenalidomide in the treatment of multiple myeloma.

Rao KV.

Am J Health Syst Pharm. 2007 Sep 1;64(17):1799-807. Review.

PMID:
17724360
20.

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.

Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2004 Aug;73(2):98-103.

PMID:
15245508
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk